Compare · DXCM vs STIM
DXCM vs STIM
Side-by-side comparison of DexCom Inc. (DXCM) and Neuronetics Inc. (STIM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STIM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 290.3x STIM ($96.7M).
- DXCM has been more active in the news (30 items in the past 4 weeks vs 15 for STIM).
- DXCM has more recent analyst coverage (25 ratings vs 4 for STIM).
- Company
- DexCom Inc.
- Neuronetics Inc.
- Price
- -
- -
- Market cap
- $28.08B
- $96.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 30
- 15
- Recent ratings
- 25
- 4
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest STIM
- Neuronetics Appoints Robert Greene as Senior Vice President Sales
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)
- Director Cucuz Sasha was granted 30,000 shares, increasing direct ownership by 2% to 1,542,798 units (SEC Form 4)
- Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 14% to 251,716 units (SEC Form 4)
- Director Cascella Robert was granted 36,250 shares, increasing direct ownership by 6% to 625,017 units (SEC Form 4)
- Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 71% to 72,500 units (SEC Form 4)
- SEC Form 8-K filed by Neuronetics Inc.
- SEC Form 8-K filed by Neuronetics Inc.